1. Meaning 

Cognitive Biomarker Governance refers to the legal, ethical, scientific, and institutional framework governing the collection, analysis, interpretation, storage, sharing, and use of biological indicators associated with cognitive functions.

Cognitive biomarkers may help identify or estimate mental processes and neurological conditions, including memory, attention, learning, cognitive impairment, and responses to treatment.

Examples include:

Neural biomarkers: EEG patterns, brain electrical activity, and certain functional brain-imaging measurements.

Molecular biomarkers: proteins or other biological substances associated with neurological disorders.

Cognitive-performance indicators: measurable patterns in memory, attention, reaction time, or executive functioning, sometimes combined with biological measurements.

AI-derived cognitive indicators: algorithmic predictions about attention, fatigue, emotional responses, or memory based on biological or neural signals.

These categories are not legally identical. A performance score is not necessarily a biological biomarker, and an algorithmic prediction is not necessarily a clinically validated finding.

The central governance question is:

How can society benefit from cognitive biomarkers without permitting unjustified surveillance, discrimination, coercion, or violations of mental privacy?

There is currently no single universally recognised statute or standalone judicial doctrine called Cognitive Biomarker Governance. Instead, the subject draws on constitutional law, medical research regulation, privacy and data-protection law, disability rights, employment law, and the law of scientific evidence. Emerging neurodata research also highlights the need to govern AI-generated inferences, not merely the original biological signals.

Sage Journals+1

2. Objectives of cognitive biomarker governance

Protection of privacy

Ensure that neural and other sensitive health data are collected and processed only under an appropriate legal basis, with effective safeguards against unauthorised disclosure and secondary use.

Scientific validity and clinical safety

Require evidence that a biomarker is sufficiently reliable for its intended purpose before it is used to diagnose a condition, guide treatment, or influence consequential decisions.

Equality and non-discrimination

Prevent unvalidated cognitive predictions from being used to unfairly exclude individuals from employment, education, insurance, or public services.

Autonomy and informed consent

Preserve the person's ability to decide whether to participate in testing or research, subject to lawful exceptions and appropriate safeguards.

Accountability and transparency

Require institutions to document their methods, explain consequential decisions, investigate errors, and provide effective routes for complaints and remedies.

3. Principal legal issues

A. Mental privacy and informational self-determination

Cognitive biomarker data can disclose or suggest information that a person has not deliberately communicated. Neural recordings may be combined with machine learning to estimate cognitive states or behavioural tendencies.

Governance must therefore distinguish between:

Collecting a biological signal.

Inferring a cognitive characteristic from that signal.

Using the inference to make a decision about a person.

Sharing the result with another institution or using it for a new purpose.

Each stage may create a different legal risk. Consent to participate in a neurological study, for example, should not automatically be interpreted as permission for an employer to use the results in recruitment.

B. Scientific validity and evidentiary reliability

A biomarker may correlate with a cognitive condition without reliably proving that a particular individual has that condition.

Responsible governance should address:

Analytical validity: whether the test measures what it claims to measure.

Clinical validity: whether the result reliably relates to the relevant clinical condition or outcome.

Clinical utility: whether using the result improves decisions or outcomes.

Reproducibility, error rates, and performance across different populations.

Independent validation of AI models and clear disclosure of uncertainty.

A cognitive biomarker should not automatically be treated as proof of intelligence, honesty, criminal propensity, competence, or future conduct.

C. Discrimination and equal treatment

A cognitive assessment may disadvantage people because of disability, neurological differences, age, language, culture, medication, fatigue, or testing conditions.

A governance framework should require decision-makers to demonstrate that a test is relevant to the actual purpose, proportionate to the risk, and supported by adequate evidence. Where applicable, disability-accommodation and anti-discrimination laws must also be considered.

D. Consent in research and clinical practice

Valid consent should ordinarily explain the purpose of testing, foreseeable risks, data retention, possible secondary uses, sharing arrangements, and the limits of confidentiality.

Research involving people with impaired decision-making capacity requires additional protections; cognitive impairment alone does not mean a person is incapable of consent.

E. Automated decisions and algorithmic accountability

When AI uses cognitive biomarkers to rank job applicants, assess students, predict insurance risk, or determine eligibility for services, institutions should examine the model's accuracy, bias, explainability, and consequences.

For example, an algorithm that labels a worker as inattentive based on EEG data could produce a harmful decision even if the original recording was collected lawfully. The inference and the decision based on it need their own scrutiny.

4. Important case laws and judicial precedents

The following cases are particularly relevant to cognitive biomarker governance. Some directly concern neurological testing or neural data; others establish legal principles that can be applied by analogy. They should not be mistaken for judgments establishing a single, comprehensive cognitive-biomarker doctrine.

Case 1: Selvi v. State of Karnataka (2010)

Supreme Court of India · (2010) 7 SCC 263

Facts: The case concerned the involuntary administration of narcoanalysis, polygraph examinations, and Brain Electrical Activation Profile (BEAP) tests during criminal investigations.

Legal issue: Whether compelling a person to undergo such techniques violated the constitutional right against self-incrimination under Article 20(3) and the protection of personal liberty under Article 21.

Judgment: The Supreme Court held that involuntary administration of the impugned techniques violated constitutional protections. It treated the results as testimonial in character for purposes of Article 20(3), rather than permitting the State to avoid constitutional safeguards merely because information was obtained through scientific instrumentation. The Court also emphasised personal liberty and mental privacy.

API Sci+1

Relevance to cognitive biomarker governance:

Biological or neural measurements should not be used to circumvent protections against compelled testimonial evidence.

Cognitive testing in criminal investigations must respect constitutional safeguards.

Scientific techniques should not be presumed reliable merely because they use sophisticated equipment.

Confidentiality of test recordings and results is important to prevent stigma and misuse.

Legal principle: Scientific access to a person's cognitive processes remains subject to constitutional protections; technology does not eliminate the requirement of consent where the Constitution demands it.

Case 2: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India, nine-judge bench · (2017) 10 SCC 1

Facts: The Court considered whether privacy is a fundamental right under the Constitution of India.

Legal issue: Whether privacy is protected as part of life, personal liberty, dignity, and the freedoms guaranteed by Part III of the Constitution.

Judgment: The Court unanimously recognised privacy as a constitutionally protected fundamental right. The judgment also addressed informational privacy and the need to balance individual rights with legitimate State interests. Restrictions on privacy must satisfy constitutional requirements, including legality, a legitimate aim, and proportionality.

Indian Kanoon+1

Relevance to cognitive biomarker governance:

Neural and cognitive data may reveal intimate information about a person.

State collection or use of such information requires appropriate legal justification.

Data protection must account for the risks posed by private organisations as well as government agencies.

The use of cognitive profiles in public administration should be assessed for necessity and proportionality.

Legal principle: Cognitive biomarker governance in India can draw upon the constitutional right to privacy, although Puttaswamy did not specifically decide the status of every category of neural or AI-inferred data.

Case 3: Girardi v. Emotiv (2023)

Supreme Court of Chile · Judgment of 9 August 2023

Facts: Former senator Guido Girardi challenged the handling of brain data collected by Emotiv's consumer EEG headset. The dispute included concerns about access to the data, storage, and possible transfer to third parties.

Legal issue: Whether the collection and handling of neurodata violated constitutional protections relating to privacy and psychological integrity.

Judgment: The Chilean Supreme Court ruled in Girardi's favour. The decision has been described in subsequent legal scholarship as a landmark in the protection of consumer neurodata.

Nature Biotechnology+1

Relevance to cognitive biomarker governance:

Consumer neurotechnology needs meaningful privacy safeguards.

Individuals should not lose practical control over highly sensitive brain data because of restrictive licensing arrangements.

Organisations must scrutinise cloud storage, data sharing, and secondary uses.

Governance must cover the lifecycle of neural data, including retention and deletion.

Legal principle: Constitutional privacy protections can have direct significance for commercial neurotechnology, not merely clinical research or criminal investigations.

This is a Chilean decision and is not binding precedent in India, although its reasoning may be persuasive in comparative legal analysis.

Case 4: Maneka Gandhi v. Union of India (1978)

Supreme Court of India · (1978) 1 SCC 248

Facts: The case challenged the impounding of Maneka Gandhi's passport and raised questions about the scope of personal liberty under Article 21.

Legal issue: Whether a procedure affecting personal liberty must satisfy standards of fairness, reasonableness, and constitutional compliance.

Judgment: The Court rejected an unduly narrow interpretation of personal liberty and held that a procedure depriving a person of liberty must be fair, just, and reasonable.

Relevance: If a public authority uses a cognitive biomarker to deny a licence, impose a restriction, or make another consequential determination, the fairness of the process may be constitutionally relevant. The person affected may need notice, an opportunity to challenge the result, and a reasoned decision, depending on the applicable legal framework.

Limitation: The case did not concern biomarkers or AI. Its relevance is the general constitutional principle governing procedures that affect personal liberty.

Case 5: State of Maharashtra v. Dr. Praful B. Desai (2003)

Supreme Court of India · (2003) 4 SCC 601

Legal significance: The Court considered the use of video-conferencing technology in recording evidence under criminal procedure.

Relevance: This case is not a cognitive-biomarker decision. It illustrates how courts may address new technological methods through existing procedural law. For biomarker evidence, the corresponding questions would concern the admissibility of the evidence, reliability of the scientific method, integrity of the data, and the opportunity to challenge expert conclusions.

Important distinction: Acceptance of one technological method in judicial proceedings does not establish the scientific validity or admissibility of all biometric, neurological, or cognitive tests.

Case 6: S. and Marper v. United Kingdom (2008)

European Court of Human Rights · Applications Nos. 30562/04 and 30566/04

Facts: The case concerned the retention of fingerprints and DNA profiles of individuals who had not been convicted of offences.

Legal issue: Whether retaining sensitive biological identifiers violated the right to respect for private life under Article 8 of the European Convention on Human Rights.

Judgment: The Court found a violation of Article 8, emphasising the privacy implications of the broad and indiscriminate retention of sensitive personal data.

Relevance: Although DNA profiles differ from cognitive biomarkers, the judgment provides a useful analogy for rules on retention, purpose limitation, proportionality, and safeguards against indiscriminate storage.

Legal principle: Collecting data for a legitimate purpose does not automatically justify retaining it indefinitely or using it for unrelated purposes.

This judgment is binding within the European Convention system as applicable to the parties and is comparative authority rather than binding Indian precedent.

5. Statutory and regulatory framework

A. India

1. Constitution of India

The principal constitutional provisions include:

Article 21: Protection of life and personal liberty, including the privacy principles recognised in Puttaswamy.

Article 20(3): Protection against compelled self-incrimination, particularly relevant to involuntary cognitive testing in criminal proceedings.

Article 14: Equality before the law and protection against arbitrary State action.

Articles 19 and 21: Potentially relevant where cognitive surveillance affects protected freedoms or personal autonomy.

2. Digital Personal Data Protection Act, 2023

The Act provides a statutory framework for processing digital personal data, including provisions concerning consent, certain legitimate uses, data-fiduciary obligations, individual rights, and grievance redressal. Its application to particular cognitive biomarker systems depends on the nature of the data, the processing involved, applicable commencement notifications, and statutory exceptions.

India Code

A critical distinction is that India's 2023 Act does not establish a separate, comprehensive legal category specifically for all cognitive biomarkers. Organisations must determine how the particular data and processing activities fall within the applicable law.

3. Clinical research and medical-device regulation

Where a cognitive biomarker is used in clinical research, diagnosis, or a medical device, additional requirements may apply under the New Drugs and Clinical Trials Rules, 2019, applicable ethics-committee requirements, and the Medical Devices Rules, 2017, depending on the study or product.

The regulatory questions include whether the device is appropriately validated, whether the research has the required ethical approval, and whether participants have received adequate information.

B. European Union

The General Data Protection Regulation (GDPR) is important where its territorial and material scope applies.

Relevant provisions include:

Article 5: Principles such as purpose limitation, data minimisation, and storage limitation.

Article 6: Lawful bases for processing personal data.

Article 9: Additional restrictions on processing specified categories of sensitive personal data, including health data.

Article 22: Safeguards relating to certain solely automated decisions with legal or similarly significant effects.

Article 35: Data protection impact assessments for processing likely to result in high risks to individuals.

Whether a particular neural signal or inferred cognitive characteristic falls within a specific GDPR category depends on its nature, context, and use. The fact that data were generated by an AI system does not automatically place them outside data-protection law.

ICO+1

The EU AI Act may also apply where a cognitive assessment system falls within its scope and risk classification. Its obligations depend on the system's purpose, deployment context, and any applicable exclusions or prohibited-practice rules.

C. International human-rights framework

The International Covenant on Civil and Political Rights protects privacy under Article 17 and addresses freedom of thought under Article 18. The Convention on the Rights of Persons with Disabilities is also relevant when cognitive testing affects autonomy, legal capacity, accessibility, or equal participation.

These instruments provide important standards for developing governance systems, although their domestic enforceability and implementation vary by jurisdiction.

6. A practical governance model

An effective institutional framework should cover the full lifecycle of a cognitive biomarker.

Stage 1 — Define the purpose

Specify whether the biomarker is intended for research, clinical diagnosis, rehabilitation, workplace monitoring, or another use.

Stage 2 — Establish legal authority

Identify the lawful basis for collecting and processing the data, the consent requirements, and any restrictions on compulsory testing.

Stage 3 — Validate the biomarker

Assess scientific reliability, clinical relevance, error rates, population differences, and limitations of the measurement.

Stage 4 — Protect the data

Restrict access, define retention periods, secure transfers, and establish controls over third-party processing and AI training.

Stage 5 — Review consequential decisions

Provide appropriate human review, explanations, correction mechanisms, and ways to challenge decisions based on cognitive assessments.

Stage 6 — Monitor and remedy

Audit performance and discrimination, investigate breaches, document incidents, and provide appropriate corrective measures and legal remedies.

7. Application to hypothetical situations

These examples illustrate how the same technology can raise different legal questions depending on who uses it and why.

8. Key challenges and unresolved questions

The principal unresolved issues are:

Ownership and control: Whether individuals should have stronger rights over raw neural data and AI-generated inferences.

Inference protection: How to regulate predictions about memory, attention, emotions, or cognitive impairment even when the original data have been anonymised.

Scientific uncertainty: How much evidence is required before a biomarker can legitimately influence a high-stakes decision.

Mental autonomy: When cognitive monitoring becomes coercive or interferes with freedom of thought.

Liability: Who should be responsible when a faulty biomarker or algorithm causes injury or discrimination.

Cross-border processing: Which rules apply when neural data are collected in one country, processed in another, and used in a third.

Access and disability rights: How to prevent cognitive testing from becoming a mechanism for excluding people with disabilities or neurological differences.

Recent OECD analysis identifies mental privacy, consent, discrimination, and AI-generated inferences as central neurodata-governance concerns. It also highlights the importance of technical safeguards and risk-based oversight.

OECD+1

9. Conclusion

Cognitive Biomarker Governance is an emerging interdisciplinary legal framework concerned with ensuring that biological measurements and computational inferences about cognition are used lawfully, scientifically, and fairly.

The most significant judicial foundations include:

Selvi v. State of Karnataka (2010) — involuntary cognitive testing and constitutional protections.

Justice K.S. Puttaswamy v. Union of India (2017) — privacy, dignity, and informational autonomy.

Girardi v. Emotiv (2023) — constitutional protection of consumer neurodata in Chile.

Maneka Gandhi v. Union of India (1978) — fairness and personal liberty.

S. and Marper v. United Kingdom (2008) — proportionality and retention of sensitive biological data.

Together, these authorities support an important proposition: the ability to measure or infer aspects of human cognition does not, by itself, confer legal authority to collect, retain, disclose, or act upon that information.

For a more advanced legal study, the next useful step would be to examine Cognitive Biomarker Accountability Governance Doctrine, focusing on institutional liability, remedies for misuse, and judicial review of AI-generated cognitive assessments.